ClinicalTrials.gg
CompletedNCT00892281Updated Aug 25, 2022Results posted

ORCA - Oracea® for Rosacea: A Community-based Assessment

A Phase 4 interventional study of doxycycline (Oracea®) 40 mg modified release as monotherapy and doxycycline (Oracea®) 40 mg modified release as add-on therapy in Rosacea, sponsored by Galderma R&D. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-25.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,421
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
Largest of 12
1,421 · median 150
Started
2009
the only one that year
Phase 4
6 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
Galderma R&D

Among the 12 studies testing doxycycline in Rosacea, this one has the largest enrollment, is the only one that started in 2009, is one of 6 in phase 4, and was the 4th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 22 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

The objective of this study is to assess the effectiveness, safety, subject satisfaction and quality of life with Oracea® when used as monotherapy or as add-on therapy to existing topical regimens for the treatment of rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females aged 18 and older
  • Subjects with diagnosis of rosacea (IGA of 2 to 4)

Exclusion criteria

Exclusion Criteria:

  • Subjects who used a topical or systemic acne treatment within 4 months of the baseline visit (retinoids and isotretinoin)
  • Subjects who used a topical or systemic antibiotic within 4 weeks of the baseline visit
  • Subjects who had laser or IPL (intense pulsed light) treatments within 3 months of the baseline visit and/or who plan to have these treatments during the study
  • Subjects who have a known to tetracyclines or ingredients of the add on medications
  • Subjects who have stomach or GI problems, kidney disease or have an active systemic fungal infection or a vaginal yeast infection are excluded
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,421 participants (actual)

Study arms

  • Other
    Oracea® as monotherapy

    Oracea as monotherapy

    Drug: doxycycline (Oracea®) 40 mg modified release as monotherapy

  • Other
    Oracea® as add-on therapy

    Oracea® as add-on Therapy (Oracea® + Metronidazoles and/or Azelaic Acids and/or Sodium Sulfacetamides

    Drug: doxycycline (Oracea®) 40 mg modified release as add-on therapy

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint

    Number of participants with a change (Week 12 minus Baseline) in Investigator's Global Assessment (IGA) score. IGA is measured on a scale from 0 - 4 with 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint

    Number of participants with a change (Week 12 minus Baseline) in Clinician's Erythema Assessment Scale (CEA) score. Clinician's Erythema Assessment Scale (CEA) is a scale from 0 - 4 with 0 = None; 1 = Mild; 2 = Moderate; 3 = Significant; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12 in CEA.

    Time frame: Baaseline to Week 12

  2. Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)

    Number of treatment responders at week 12, where response is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (near clear). IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best and 4 being worst.

    Time frame: Baseline to Week 12

07

Results

Posted Nov 18, 2010

Participant flow

Dates of recruitment period: First subject was enrolled on April 30, 2009 and the last subject enrolled was on July 31, 2009. Types of location: Investigative sites were located at academic institutions and private physician offices.

Participant flow — Overall Study
MilestoneOracea® as MonotherapyOracea® as add-on Therapy
Started1197224
Completed930187
Not completed26737
Withdrew: Adverse event658
Withdrew: Lost to follow-up818
Withdrew: Pregnancy10
Withdrew: Protocol violation72
Withdrew: Withdrawal by subject8614
Withdrew: Subject failed to return for final visit20
Withdrew: Subject unable to keep follow-up visits10
Withdrew: Final visit completed 4 weeks late01
Withdrew: Subject completed day after study closed10
Withdrew: Family emergency10
Withdrew: Last visit not done - death in family10
Withdrew: Did not meet incl/excl criteria10
Withdrew: Rosacea cleared; subject d/c'd self10
Withdrew: Unable to redeem the drug voucher10
Withdrew: Subject not good candidate for study10
Withdrew: Subject did not return for any visits10
Withdrew: Subject missed several visits/lost meds10
Withdrew: Missed visit 4 and off meds for 65 days11
Withdrew: Scheduled for knee replacement01
Withdrew: Pi complained of inadequate compensation30
Withdrew: Subject lost interest in program01
Withdrew: Bad taste in mouth after taking oracea®01
Withdrew: Death in family10
Withdrew: Lack of efficacy of study product20
Withdrew: Subject not seen by pi at final visit10
Withdrew: No show visit 2; prescription not filled10
Withdrew: Missed multiple visits10
Withdrew: Missed visits rescheduled out of window10
Withdrew: Non-compliant with visits as scheduled10
Withdrew: Subject had history of drug abuse10
Withdrew: Rash on hand10
Withdrew: Visit 4 date out of window10

Outcome measures

PrimaryChange in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint

Number of participants with a change (Week 12 minus Baseline) in Investigator's Global Assessment (IGA) score. IGA is measured on a scale from 0 - 4 with 0 = Clear; 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Change in Investigator's Global Assessment (IGA) Score From Baseline to Endpoint
participantsOracea® as MonotherapyOracea® as add-on Therapy
+4 (worsening of rosacea by 4 IGA scale levels00
+3 (worsening of rosacea by 3 IGA scale levels)00
+2 (worsening of rosacea by 2 IGA scale levels)00
+1 (worsening of rosacea by 1 IGA scale level)44
0 (no change in IGA scale level)7011
-1 (improvement of rosacea by 1 IGA scale level25442
-2 (improvement of rosacea by 2 IGA scale levels)36565
-3 (improvement of rosacea by 3 IGA scale levels)12314
-4 (improvement of rosacea by 4 IGA scale levels)104
SecondaryChange in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint

Number of participants with a change (Week 12 minus Baseline) in Clinician's Erythema Assessment Scale (CEA) score. Clinician's Erythema Assessment Scale (CEA) is a scale from 0 - 4 with 0 = None; 1 = Mild; 2 = Moderate; 3 = Significant; and 4 = Severe. Results values (+4, +3, +2, +1, 0, -1, -2, -3, -4) represent change from Baseline to Week 12 in CEA.

Time frame:
Baaseline to Week 12
Reported as:
Number · participants
Change in Clinician's Erythema Assessment Scale (CEA) Score From Baseline to Endpoint
participantsOracea® as MonotherapyOracea® as add-on Therapy
+4 (worsening of erythema by 4 CEA scale levels)00
+3 (worsening of erythema by 3 CEA scale levels)00
+2 (worsening of erythema by 2 CEA scale levels)00
+1 (worsening of erythema by 1 CEA scale level)62
0 (no change in CEA scale level)9718
-1 (improvement in erythema by 1 CEA scale level)41576
-2 (improvement in erythema by 2 CEA scale levels)26138
-3 (improvement in erythema by 3 CEA scale levels)456
-4 (improvement of erythema by 4 CEA scale levels)20
SecondaryNumber of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)

Number of treatment responders at week 12, where response is defined as an Investigator's Global Assessment (IGA) score of 0 (clear) or 1 (near clear). IGA is measured on a scale from 0 - 4 with 0 = Clear, 1 = Near Clear; 2 = Mild; 3 = Moderate; and 4 = Severe with 0 being best and 4 being worst.

Time frame:
Baseline to Week 12
Reported as:
Number · participants
Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)
participantsOracea® as MonotherapyOracea® as add-on Therapy
Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)616106

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Oracea® as Monotherapy—5/1,196 (0.4%)0/1,196 (0%)
Oracea® as add-on Therapy—0/224 (0%)0/224 (0%)
Most frequent serious events
Most frequent serious events
EventOracea® as MonotherapyOracea® as add-on Therapy
Angina pectorisCardiac disorders1/11960/224
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/11960/224
Cardiac disorderCardiac disorders1/11960/224
Cerebrovascular accidentNervous system disorders1/11960/224
Thrombophlebitis superficialVascular disorders1/11960/224

Baseline characteristics

Age, Continuous
Age, Continuous(years)Oracea® as MonotherapyOracea® as add-on TherapyTotal
>=18 years50.2 ± 13.953.4 ± 12.950.7 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Oracea® as MonotherapyOracea® as add-on TherapyTotal
Female8531541007
Male34470414
08

Study locations

1 site
  • REGISTRAT® - MAP1, Inc. (CRO)
    Lexington, Kentucky 40504-3276, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2009
First posted
May 4, 2009
Start
Apr 2009
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Nov 18, 2010
Last update
Aug 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00892281
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
May 4, 2009
Start date
Apr 2009
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Nov 18, 2010
Last update
Aug 25, 2022

Study contacts

Ronald W Gottschalk, MD
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxycycline

Start the discussion